Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ImmunityBio Inc.

    NASDAQ: IBRX · Real-Time Price · USD
    3.13
    0.06 (1.95%)
    At close: Jun 16, 2025, 3:59 PM
    3.09
    -1.12%
    After-hours: Jun 16, 2025, 07:59 PM EDT

    ImmunityBio Statistics

    Share Statistics

    ImmunityBio has 882.62M shares outstanding. The number of shares has increased by 23.41% in one year.

    Shares Outstanding

    n/a
    		 882.62M

    Shares Change (YoY)

    n/a
    		 23.41%

    Shares Change (QoQ)

    n/a
    		 16.88%

    Owned by Institutions (%)

    n/a
    		 11.88%

    Shares Floating

    n/a
    		 91.82M

    Failed to Deliver (FTD) Shares

    n/a
    		 317

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 72.12M, so 8.17% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 72.12M

    Short % of Shares Out

    n/a
    		 8.17%

    Short % of Float

    n/a
    		 31.57%

    Short Ratio (days to cover)

    n/a
    		 8.68

    Valuation Ratios

    The PE ratio is -4.32 and the forward PE ratio is -10.55. ImmunityBio's PEG ratio is 0.09.

    PE Ratio

    n/a
    		 -4.32

    Forward PE

    n/a
    		 -10.55

    PS Ratio

    n/a
    		 121.07

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 -3.66

    P/FCF Ratio

    n/a
    		 -4.48

    PEG Ratio

    n/a
    		 0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for ImmunityBio.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.36, with a Debt / Equity ratio of -1.03.

    Current Ratio

    n/a
    		 3.36

    Quick Ratio

    n/a
    		 3.21

    Debt / Equity

    n/a
    		 -1.03

    Debt / EBITDA

    n/a
    		 -2.09

    Debt / FCF

    n/a
    		 -1.27

    Interest Coverage

    n/a
    		 -2.23

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $21,974.66

    Profits Per Employee

    n/a
    		 $-616,339.79

    Employee Count

    n/a
    		 671

    Asset Turnover

    n/a
    		 0.04

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 81K

    Effective Tax Rate

    n/a
    		 -0.02%

    Stock Price Statistics

    The stock price has increased by -46.48% in the last 52 weeks. The beta is -0.07, so ImmunityBio's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.07

    52-Week Price Change

    n/a
    		 -46.48%

    50-Day Moving Average

    n/a
    		 2.65

    200-Day Moving Average

    n/a
    		 3.37

    Relative Strength Index (RSI)

    n/a
    		 58.91

    Average Volume (20 Days)

    n/a
    		 9,128,217

    Income Statement

    In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.

    Revenue

    n/a
    		 14.74M

    Gross Profit

    n/a
    		 -2.81M

    Operating Income

    n/a
    		 -344.18M

    Net Income

    n/a
    		 -413.56M

    EBITDA

    n/a
    		 -241.76M

    EBIT

    n/a
    		 -281.99M

    Earnings Per Share (EPS)

    n/a
    		 -0.59
    Full Income Statement

    Balance Sheet

    The company has 143.43M in cash and 504.17M in debt, giving a net cash position of -360.74M.

    Cash & Cash Equivalents

    n/a
    		 143.43M

    Total Debt

    n/a
    		 504.17M

    Net Cash

    n/a
    		 -360.74M

    Retained Earnings

    n/a
    		 -3.38B

    Total Assets

    n/a
    		 303.76M

    Working Capital

    n/a
    		 59.96M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -391.24M and capital expenditures -6.89M, giving a free cash flow of -398.12M.

    Operating Cash Flow

    n/a
    		 -391.24M

    Capital Expenditures

    n/a
    		 -6.89M

    Free Cash Flow

    n/a
    		 -398.12M

    FCF Per Share

    n/a
    		 -0.57
    Full Cash Flow Statement

    Margins

    Gross margin is -19.05%, with operating and profit margins of -2334.23% and -2804.77%.

    Gross Margin

    n/a
    		 -19.05%

    Operating Margin

    n/a
    		 -2334.23%

    Pretax Margin

    n/a
    		 -2804.77%

    Profit Margin

    n/a
    		 -2804.77%

    EBITDA Margin

    n/a
    		 -1639.63%

    EBIT Margin

    n/a
    		 -2334.23%

    FCF Margin

    n/a
    		 -2700.06%

    Dividends & Yields

    IBRX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for IBRX is $8, which is 156.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 156.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.67

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist